The Increasing prevalence of tuberculosis and the introduction of novel genome tuberculosis testing are expected to lead the global tuberculosis diagnostics market

calendar_today 07 October, 2022 person_outline Growth Plus Reports

According to the deep-dive market assessment study conducted by Growth+ Reports, the global tuberculosis diagnostics market was valued at ~US$ 1.8 billion in 2021. The market is expected to witness a CAGR of ~4.10 % from 2022 to 2030.  

Tuberculosis (TB) is a highly infectious and deadly because of its high antibiotic resistance ability. Tuberculosis is caused by mycobacterium tuberculosis bacteria (MTB). It primarily attacks the lungs, and after doing severe damage to the lungs may spread to any part of the body, such as the nervous system, glands, bones, organs, etc. Tuberculosis (TB) can spread from one person to another through the droplets dispersed in the air via sneezes and coughs by an infected person. Infected persons experience symptoms like coughing up blood, breathlessness, high fever, night sweats, weakness, loss of appetite, and sudden weight loss. Many tests are available for diagnosing tuberculosis (TB), i.e., radiographic tests, microscopy, molecular testing, culture, and sensitivity test, skin antigen testing, genetic testing, and drug resistance test. 

Increasing HIV and AIDS transmission contributes to the tuberculosis diagnostics market as HIV and AIDS patients have lower immune systems compared to ordinary healthy people. Such patients have compromised immunity to fight against TB bacteria, making them more vulnerable to TB and other infections. According to the Centers for Disease Control and Prevention, in 2019, nearly 34,800 new HIV cases were reported in the United States. It is estimated that in 2019 around 1,189,700 people in the United States had HIV. The increasing number of HIV-infected patients and the high HIV transmission rate contribute to the growth of the global tuberculosis diagnostics market.  

Tuberculosis is the world's 13th leading cause of death and the world's second most infectious and dangerous disease after COVID-19. Tuberculosis is treatable if diagnosis and treatment are made in the early stages. In June 2021, the World Health Organization (WHO) released a list of high-burden countries that have high numbers of tuberculosis (TB) and multidrug-resistant (MDR/TB). Out of 30 countries that have a high burden of tuberculosis, India is leading the count with the presence of 19,33,381 active cases, followed by Pakistan, China, Indonesia, Philippines, Nigeria, Bangladesh, and South Africa. World Health Organization reported in October 2021 that almost 1.5 million people died from tuberculosis (TB) among nearly 214,000 people who had HIV. Almost 10 million people are diagnosed with tuberculosis (TB) worldwide, of which 1.1 million are children, 5.6 million are men, and 3.3 million are women. 

Molecular tests aim to detect tuberculosis bacterial nucleic acids, RNA, and DNA using polymerase chain reaction (PCR). Molecular testing amplifies the DNA or RNA by making multiple copies of bacterial infection, which make diagnosis more precise for qualification and quantification. Molecular testing is leading the global tuberculosis diagnostics market owing to the exact diagnosis and ease of calculating viral load to understand the severity of infection. Additionally, technological advancement, less turnaround time, high sensitivity, and high specificity are contributing to the growth of the molecular testing market.

Conversely, the global tuberculosis diagnostics market holds the high cost of genome sequencing and molecular testing, expensive reagents, and testing analyzers. Genome testing is expensive as genome sequencer equipment costs between US$ 800,000 and US$ 900,000. It requires at least 100-200 samples to run the sequencing process on the testing chip. Even for a lower sample count, the testing chip costs the same. Furthermore, high sample rejection due to the inability to meet quality standards makes genome sequencing tests expensive.

Based on region, the global tuberculosis diagnostics market has been segmented into Based on the region as North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global tuberculosis diagnostics market, followed by the Asia Pacific. The large share of North America in the global market can be attributed to developed infrastructure, high expenditure on healthcare, technological advancement, and the adoption of novel technology for tuberculosis (TB) diagnosis. Asia Pacific is also expected to show exponential growth owing to the high prevalence of tuberculosis (TB), large population, increasing awareness about tuberculosis, developing infrastructure, and emerging regional diagnostics companies. Government initiatives for tuberculosis diagnosis and treatment also contribute to the Asia Pacific tuberculosis (TB) diagnostics market.

Some prominent players operating in the global tuberculosis diagnostics market are Abbott Laboratories Inc., Becton, Dickinson, and Company, BioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hain Lifescience GmbH, Hologic Inc., Oxford Immunotec, QIAGEN, and Thermo Fisher Scientific Inc. among others.

awards awards key differentiators

Reach Us

Web –

// // // //